Figure 4.
Biological effects of custirsen (OGX-011) on clusterin expression and apoptotic index in prostate tumor cells from prostatectomy specimens. (A) Box plot of clusterin protein levels in prostate tumor samples from men treated with custirsen and untreated historical controls. (B) Apoptotic index (percentage apoptotic cells and bodies per 10 high-power fields) in prostatectomy specimens and untreated historical controls.65
Notes: Boxes represent interquartile ranges, and lines extending from the boxes represent the closer of 1.5 times the interquartile range, or the most extreme observation. Lines across the boxes represent the median, and circles represent outliers. Reproduced from Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave M. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. Journal of the National Cancer Insitute. 2005;97(17):1287–1296, by permission of Oxford University Press.65
Abbreviations: <2M NHT, less than two months of neoadjuvant hormone therapy; NT, no prior treatment.